Figure S8 from Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis

Supplementary Figure S8: (A) PK data for AZD9668, when administered by intraperitoneal (I.P.) injection at a concentration of 100mg/kg. N=3 mice were used per timepoint, and the t1/2 of the drug was calculated to 2.16 hours. (B) Specificity of AZD9668 to inhibit NE activity was confirmed in vitro using a NE-specific substrate, under indicated doses of AZD9668. AZD5069 (CXCR2 antagonist) was used as a negative control. (C) Whole body weights of PyMT NE+/+ mice treated with either Vehicle (black) or 100mg/kg AZD9668 (pink) every day, BID for 60 consecutive days. (D, E) Western blot analysis done on endpoint tumors, to confirm NE activity in (D) PyMT NE+/+ and PyMT NE-/- mice and (E) PyMT NE+/+ mice treated with either Vehicle or 100mg/kg AZD9668, as described in Figure 5 of main text.